Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALIM

ALIM - Alimera Sciences Inc Stock Price, Fair Value and News

3.31USD+0.06 (+1.85%)Market Closed
Watchlist

Market Summary

USD3.31+0.06
Market Closed
1.85%

ALIM Stock Price

View Fullscreen

ALIM RSI Chart

ALIM Valuation

Market Cap

173.5M

Price/Earnings (Trailing)

-8.62

Price/Sales (Trailing)

2.53

EV/EBITDA

-41.06

Price/Free Cashflow

-9.36

ALIM Price/Sales (Trailing)

ALIM Profitability

EBT Margin

-26.40%

Return on Equity

-41.22%

Return on Assets

-13.06%

Free Cashflow Yield

-10.69%

ALIM Fundamentals

ALIM Revenue

Revenue (TTM)

68.5M

Rev. Growth (Yr)

71.82%

Rev. Growth (Qtr)

33.22%

ALIM Earnings

Earnings (TTM)

-20.1M

Earnings Growth (Yr)

74.24%

Earnings Growth (Qtr)

86.5%

Breaking Down ALIM Revenue

Last 7 days

-12.1%

Last 30 days

-12.1%

Last 90 days

3.6%

Trailing 12 Months

42.8%

How does ALIM drawdown profile look like?

ALIM Financial Health

Current Ratio

2.73

ALIM Investor Care

Shares Dilution (1Y)

647.91%

Diluted EPS (TTM)

-2.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202355.8M58.7M68.5M0
202259.7M52.6M54.1M54.1M
202147.5M59.2M58.8M59.0M
202055.6M54.8M54.4M50.8M
201949.9M50.0M51.7M53.9M
201838.9M39.3M40.6M46.6M
201735.1M36.0M37.4M35.9M
201624.3M28.1M29.5M34.3M
201510.3M13.9M18.4M22.4M
20143.5M5.1M6.8M8.4M
20130001.9M

Tracking the Latest Insider Buys and Sells of Alimera Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 10, 2024
ashman philip
sold (taxes)
-11,343
3.861
-2,938
president of int'l operations
Oct 02, 2023
eiswirth richard s jr
acquired
-
-
400,000
president and ceo
Oct 02, 2023
werner jason m.
acquired
-
-
225,000
chief operating officer
Sep 14, 2023
caligan partners lp
bought
1,962,810
3.39
579,000
-
Sep 14, 2023
caligan partners lp
sold
-1,962,810
3.39
-579,000
-
Aug 15, 2023
caligan partners lp
acquired
6,142,000
2.1
2,924,760
-
Aug 15, 2023
morgan adam
acquired
14,379,200
1.85056
7,770,150
-
Aug 15, 2023
caligan partners lp
acquired
22,833,700
1.7
13,431,600
-
Aug 15, 2023
morgan adam
acquired
7,103,830
1.7
4,178,720
-
May 17, 2023
morgan adam
bought
2,383,230
1.7
1,401,900
-

1–10 of 50

Which funds bought or sold ALIM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
sold off
-100
-
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
85,856
85,856
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-51.11
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
342
2,348,760
2,803,480
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
24,400
86,400
-%
Feb 14, 2024
Balyasny Asset Management L.P.
new
-
172,938
172,938
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-63.86
-138,182
140,232
-%
Feb 14, 2024
PERRITT CAPITAL MANAGEMENT INC
sold off
-100
-31,000
-
-%

1–10 of 42

Are Funds Buying or Selling ALIM?

Are funds buying ALIM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALIM
No. of Funds

Unveiling Alimera Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
lytton laurence w
4.2%
2,185,364
SC 13G/A
Feb 13, 2024
altium capital management lp
5.0%
2,660,000
SC 13G/A
Feb 13, 2024
boothbay fund management, llc
6.1%
3,198,708
SC 13G/A
Feb 13, 2024
stonepine capital management, llc
9.99%
5,373,732
SC 13G/A
Feb 13, 2024
hbm healthcare investments (cayman) ltd.
0.9%
466,666
SC 13G/A
Dec 08, 2023
morgan stanley
1.8%
916,246
SC 13G/A
Aug 23, 2023
altium capital management lp
5.7%
2,984,803
SC 13G
Aug 16, 2023
velan capital investment management lp
18.0%
9,429,808
SC 13D/A
Aug 14, 2023
lytton laurence w
5.7%
2,984,803
SC 13G
Aug 10, 2023
boothbay fund management, llc
8.99%
4,784,480
SC 13G

Recent SEC filings of Alimera Sciences Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
8-K
Current Report
Feb 09, 2024
S-8
Employee Benefits Plan
Feb 09, 2024
S-8
Employee Benefits Plan
Jan 11, 2024
4
Insider Trading
Jan 04, 2024
3
Insider Trading

Peers (Alternatives to Alimera Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
22.4M
84.1M
58.23% -28.98%
-1.05
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Alimera Sciences Inc News

Latest updates
InvestorsObserver22 hours ago
Simply Wall St30 Dec 202308:00 am

Alimera Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue33.2%23,36417,53813,54614,02913,59814,60411,89813,95912,15321,70311,21413,77412,47310,03814,53517,34812,85010,85512,89015,11511,137
Gross Profit36.3%20,60615,11311,51811,90411,59212,43810,21811,99310,46419,8909,65211,78210,9368,55312,60815,07511,2719,68111,29013,78910,172
Operating Expenses14.9%18,75216,32114,82014,01215,00314,41214,36514,74512,48612,88712,08211,60910,5299,85212,39013,64812,98713,27112,68513,71712,367
  S&GA Expenses23.4%7,9406,4345,8045,7656,5046,8656,8537,1695,7515,3314,8184,9864,9624,5665,8708,4896,4376,1083,3933,9953,446
  R&D Expenses10.9%4,0453,6484,1644,2304,4833,9323,5833,7203,2783,5673,2132,5062,4691,8102,8832,6702,7612,8342,7272,8762,799
EBITDA Margin48.4%-0.07*-0.13*-0.16*-0.18*0.08*0.08*0.07*0.07*0.12*0.18*0.00*0.05*0.07*--------
Interest Expenses22.2%2,0701,6941,6671,6341,5001,3831,3641,3631,3601,3471,3431,4521,2851,3511,2921,1731,2321,2361,2281,2351,211
Income Taxes112.0%53.0025.00--10.0012.0017.0018.00-35.00-1696404.00-1237.005.0043.00-19377.0026171.002.0028.00
Earnings Before Taxes87.0%-1,301-10,004--3,781-5,245-3,098--4,139-4,3528,205-3,648-1,100-611-2,541-1,155305-3,063-4,777-2,692-1,246-3,422
EBT Margin14.3%-0.26*-0.31*-0.32*-0.33*-0.07*-0.07*-0.07*-0.07*-0.02*0.05*-0.17*-0.11*-0.07*--------
Net Income86.5%-1,354-10,029-4,968-3,780-5,257-3,115-5,955-4,106-4,1837,565-3,648-977-618-2,546-1,198498-3,140-5,038-2,763-1,248-3,450
Net Income Margin28.2%-0.29*-0.41*-0.31*-0.33*-0.34*-0.33*-0.11*-0.07*-0.02*0.04*-0.16*-0.11*-0.07*--------
Free Cashflow-59.6%-9,830-6,158-2,218-335-2,043-1,490-6,362-4,804-3,0426,586-2,585-348-2,466--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.5%15415548.0043.0043.0048.0050.0059.0060.0062.0046.0051.0049.0049.0049.0050.0047.0050.0052.0054.0051.00
  Current Assets5.2%48.0046.0036.0029.0030.0033.0035.0042.0044.0045.0030.0035.0033.0032.0032.0033.0028.0031.0033.0035.0031.00
    Cash Equivalents-55.9%8.0019.0013.005.006.008.0010.0017.0022.0025.008.0011.0011.0014.0012.009.008.0012.0013.0013.0013.00
  Inventory66.8%2.001.001.002.002.002.002.003.002.002.003.003.003.002.001.001.002.002.002.002.002.00
  Net PPE-0.9%2.002.002.003.002.002.003.003.002.002.002.002.002.001.001.001.001.001.001.001.002.00
  Current Liabilities24.4%18.0014.0014.0040.0034.0025.0017.0013.0011.0010.0011.0012.0010.0010.009.0012.0014.0012.0010.0010.008.00
Shareholder's Equity5.6%49.0046.003783783783783783772.006.003663663533513503503493481.003.003.00
  Retained Earnings-0.5%-414-412-402-415-411-406-403-397-393-388-396-392-391-391-388-387-388-384-379-377-375
  Additional Paid-In Capital19.3%462387378378378378378377377376366366353351350350348348347347345
Shares Outstanding495.4%52.009.007.007.007.007.007.007.006.007.006.006.005.00--------
Float------31.00---60.00---30.00---60.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-63.9%-9,826-5,996-2,209-251-1,913-1,598-6,213-4,683-2,7326,692-2,501-263-2,148-330548422-3,898-960284660-3,811
  Share Based Compensation-18.2%12114822621713421831227220722426255322.0021.00440-1,711504629770-2,8731,032
Cashflow From Investing100.0%-4.00-75,434-9.00-84.00-130108-149-121-310-106-84.00-85.00-318-192-25.00-24.00-111-24.00-15.00-1.00-51.00
Cashflow From Financing-100.6%-54687,1259,998-19355.00-102-62.00-19.00-49.009,948-57.00-46.00-1101,6232,4151,069-58.00-32.00-110-25.00-203
  Dividend Payments----------------------
  Buy Backs-100.0%-18,603-18,289------------------

ALIM Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations [Abstract]    
NET REVENUE$ 23,364$ 13,598$ 54,448$ 40,100
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION(2,758)(2,006)(7,211)(5,852)
GROSS PROFIT20,60611,59247,23734,248
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES4,0454,48311,85711,998
GENERAL AND ADMINISTRATIVE EXPENSES3,6073,35212,1519,537
SALES AND MARKETING EXPENSES7,9406,50420,17820,222
DEPRECIATION AND AMORTIZATION3,1606645,7072,023
OPERATING EXPENSES18,75215,00349,89343,780
INCOME (LOSS) FROM OPERATIONS1,854(3,411)(2,656)(9,532)
INTEREST EXPENSE AND OTHER(2,070)(1,500)(5,431)(4,247)
UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET(138)(67)(158)79
LOSS ON EXTINGUISHMENT OF DEBT  (1,079) 
CHANGE IN FAIR VALUE OF WARRANT ASSET(22)(267)(113)(598)
CHANGE IN FAIR VALUE OF WARRANT LIABILITY(925) (6,836) 
NET LOSS BEFORE TAXES(1,301)(5,245)(16,273)(14,298)
INCOME TAX PROVISION(53)(12)(78)(29)
NET LOSS(1,354)(5,257)(16,351)(14,327)
PREFERRED STOCK DIVIDENDS(576) (1,259) 
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS$ (1,930)$ (5,257)$ (17,610)$ (14,327)
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Basic$ (0.06)$ (0.75)$ (1.11)$ (2.05)
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Diluted$ (0.06)$ (0.75)$ (1.11)$ (2.05)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic32,106,0146,996,57515,835,8076,995,695
WEIGHTED AVERAGE SHARES OUTSTANDING — Diluted32,106,0146,996,57515,835,8076,995,695

ALIM Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 8,285$ 5,274
Restricted cash3130
Accounts receivable, net33,94319,612
Prepaid expenses and other current assets4,3832,892
Inventory1,7601,605
Total current assets48,40229,413
NON-CURRENT ASSETS:  
Property and equipment, net2,4422,525
Right-of-use assets, net1,1761,395
Intangible assets, net101,9758,957
Deferred tax asset127129
Warrant asset70183
TOTAL ASSETS154,19242,602
CURRENT LIABILITIES:  
Accounts payable6,20510,088
Accrued expenses6,0103,998
Accrued licensor payments5,313 
Notes payable 25,313
Finance lease obligations193333
Total current liabilities17,72139,732
NON-CURRENT LIABILITIES:  
Notes payable, net of discount64,22218,683
Accrued licensor payments17,537 
Other non-current liabilities5,8724,995
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY (DEFICIT):  
Common stock, $.01 par value — 150,000,000 shares authorized, 52,416,841 shares issued and outstanding at September 30, 2023 and 6,995,513 shares issued and outstanding at December 31, 202252470
Common stock warrants4,396 
Additional paid-in capital461,622378,238
Accumulated deficit(414,708)(415,388)
Accumulated other comprehensive loss(2,994)(2,955)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)48,840(20,808)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)$ 154,19242,602
Series A Preferred Stock [Member]  
STOCKHOLDERS’ EQUITY (DEFICIT):  
Preferred stock, $.01 par value — 10,000,000 shares authorized at September 30, 2023 and December 31, 2022: Series A Convertible Preferred Stock, none authorized, issued and outstanding at September 30, 2023; 1,300,000 authorized and 600,000 issued and outstanding at December 31, 2022; liquidation preference of $24,000 at December 31, 2022 $ 19,227
ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEalimerasciences.com
 EMPLOYEES150

Alimera Sciences Inc Frequently Asked Questions


What is the ticker symbol for Alimera Sciences Inc? What does ALIM stand for in stocks?

ALIM is the stock ticker symbol of Alimera Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alimera Sciences Inc (ALIM)?

As of Thu Feb 22 2024, market cap of Alimera Sciences Inc is 173.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALIM stock?

You can check ALIM's fair value in chart for subscribers.

What is the fair value of ALIM stock?

You can check ALIM's fair value in chart for subscribers. The fair value of Alimera Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alimera Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alimera Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALIM is over valued or under valued. Whether Alimera Sciences Inc is cheap or expensive depends on the assumptions which impact Alimera Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALIM.

What is Alimera Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ALIM's PE ratio (Price to Earnings) is -8.62 and Price to Sales (PS) ratio is 2.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alimera Sciences Inc's stock?

In the past 10 years, Alimera Sciences Inc has provided -0.286 (multiply by 100 for percentage) rate of return.